Roche Holding AG shares fell by over 5% on Monday after its investigational oral selective estrogen receptor degrader (SERD) giredestrant did not achieve a statistically significant progression-free survival (PFS) benefit in the pivotal persevERA trial. The stock traded at CHF341.20, against a 52-week high of CHF374.90 and a 52-week low of CHF231.90, as investors reassessed the drug’s market prospects.
The company said the persevERA study failed to deliver a statistically significant PFS benefit in the first-line setting for ER-positive, HER2-negative metastatic breast cancer. Roche indicated it will present the full dataset at an upcoming medical conference.
Analyst reaction and commercial implications
Jefferies, which maintains an "underperform" rating on Roche with a price target of CHF230, said the persevERA result "pulls the rug" from the commercial case for giredestrant. The bank models peak worldwide sales of CHF1.2 billion for the drug, risk-adjusted at 60 percent, compared with a VisibleAlpha consensus forecast of CHF5.8 billion at 77 percent probability.
Jefferies also noted that "although Roche emphasises a numerical improvement, this is unlikely to be clinically meaningful in a clinical setting where incremental benefit must be clear to displace entrenched therapies." The firm highlighted that the trial had targeted a hazard ratio in the range of 0.6 to 0.7.
Why the trial missed and how it compares to rival programs
According to Jefferies, the core issue in persevERA was giredestrant’s failure to demonstrate added benefit when used alongside a CDK4/6 inhibitor, which is the standard of care in this treatment setting. That outcome undercuts earlier, more positive signals from Roche’s coopERA, evERA and lidERA studies.
Jefferies subsequently raised its price target on AstraZeneca to $120 from $98 and rated the stock a buy, citing structural advantages in AstraZeneca’s camizestrant trial design. The CAMBRIA-2 study enrolls 5,500 patients versus 4,200 in Roche’s lidERA trial, allows CDK4/6 inhibitor use in both arms, accepts patients with up to 12 weeks of prior endocrine therapy and plans for seven years of treatment. By contrast, Roche’s lidERA excludes CDK4/6 inhibitors, requires no prior endocrine therapy and runs for five years. CAMBRIA-2 data are expected in 2027.
Jefferies warned that the persevERA setback is likely to "completely reverse the positive momentum from late last year" and expects the result to compress Roche’s earnings multiple from its current 17 times.
What’s next for giredestrant and Roche
Roche’s next readout for giredestrant is the pionERA trial, which the company expects to report in 2027. Roche’s market capitalisation stood at CHF276.1 billion at the time of the market move. Investors will be watching the forthcoming conference presentation for full persevERA data and awaiting the results of other trials that will determine the drug’s place relative to competitors.
Summary
The persevERA miss has immediate market consequences for Roche’s stock and reconfigures the competitive landscape for oral SERDs in metastatic ER-positive, HER2-negative breast cancer. The result reduces the near-term commercial expectations for giredestrant and elevates the importance of rival trials, notably AstraZeneca’s CAMBRIA-2 and Roche’s own ongoing studies.